ResearchSafe

Hims pulling GLP-1 pills after FDA warning, Novo jumps 8%

Posted by frugal_student in Research & News - 5 points, 5 comments.

https://www.cnbc.com/2026/02/09/europe-before-the-bell-futures-catch-asia-rally.html

CNBC is reporting that Hims is going to stop offering the compounded GLP-1 pill after the FDA signaled a crackdown, and Novo Nordisk stock popped about 8% on the news. It's a decent read because it connects the dots between telehealth regulation and the big pharma players in a way that actually matters for anyone using these meds.

My take is the oral GLP-1 space was always going to get squeezed. Compounded semaglutide pills were a gray area from day one, and the moment the FDA decided to pay attention, the telehealth shops that leaned on them were exposed. I get why people liked the convenience, but bioavailability on the oral form is rough compared to the injectable, so the clinical case was shaky too.

Question for the room, are we going to see more telehealth companies quietly retreat, or double down on the branded supply deals?

Comments

  • rational_reads: Bioavailability is the key thing here and most people skip past it. The oral sema form needs to be taken on an empty stomach with very specific water rules, even then youre getting a fraction of what the shot delivers. So the clinical case was always weaker than the marketing made it sound. Curious what you mean by telehealth shops being "exposed" though. Hims leaned on compounding pharmacies which are legal in certain contexts, thats not quite the same as the FDA coming after them directly. Is
  • aspiring_vet: Yeah the bioavailability point is huge, not gonna lie. The empty stomach rules alone mess up a lot of people who just pop it with their morning coffee and wonder why they feel nothing. On the Hims thing, my understanding is the warning hit the oral form specifically because thats what they were pushing heaviest. Compounding injectables have a clearer legal path. But youre right, its not the same as the FDA going after compounding itself, more like they picked the weakest link to make an example
  • tracker_mateo: Yeah the bioavailability point is a big one, you're right. Most people don't realise how fiddly the oral version is, basically no food for 30 min before and after, sip not gulp of water, and even then the absorption is all over the place. On the compounding question, it was framed broadly from what I saw, not just the oral. That's why a few telehealth outfits are pulling back across the board, not only the pill. The compounding loophole itself is still legal, but the FDA is clearly tightening t
  • frugal_student: Good call out on the fasting window, most people I talk to have no idea about the sip-not-gulp rule or the 30 min buffer either, they just swallow it with their coffee and wonder why they feel nothing. And yeah you might be right about the compounding crackdown being broader than just the pill, I only skimmed the CNBC piece so I may have missed that angle. Curious though, do you think the branded supply deals are actually sustainable for these telehealth shops long term, or are they just buying
  • frugal_student: Yeah, the empty stomach thing kills a lot of the real-world effectiveness for sure, people don't realize how strict that window is. And that tracks with what I read, the oral form was the soft target. Curious though, do you think the injectables stay mostly untouched, or does the FDA eventually circle back once they finish with this round?
  • frugal_student: Yeah fair point, "exposed" was sloppy phrasing on my part. I meant more that Hims built a big chunk of their GLP-1 business on a gray area product, and once the FDA looked at it the math stopped working overnight. Their own supply chain is the risk, not necessarily a direct enforcement action. On the scope question, from what CNBC wrote the warning is aimed at the oral compounded forms specifically, not all compounded GLP-1s. But you're right that the line between them gets blurry fast in pract

Community discussion - research and educational context only. Not medical advice.